Clinical observation of the treatment of acute cerebral infarction with Edaravone
Yang Yunzhou,Tang Lili,Shi Xiuli, et al (Dept of Neurology, The First Affiliated Hospital of Anhui Medical University, Hefei 230022)
Objective To evaluate efficacy and adverse reactions of Edaravone, a novel hydroxyl-free radical scavenger, on acute cerebral infarction (ACI) . Methods We performed a randomized controlled study on ACI patients. 64 patients, enrolled within 24h of onset, were allocated to Edaravone group(n=31) or control group(n=33) randomly. Before and after treatment, we assessed the neurological deficits and activities of daily living (ADL) using Chinese Stroke Scale(CSS)and Barthel Index respectively. Clinical efficacy was evaluated according to changes of CSS and ADL scores on the 21th day. Results On the 21th day, CSS and ADL were evaluted. There was a significant difference of CSS scores between Edaravone group and the control group (P0.05). There was a significant difference of ADL scores between Edaravone group and the control group (P0.001). There was no distinct adverse reaction in Edaravone group. Conclusion Edaravone can improve the neurological function impairment and activities of daily living of acute cerebral infarction patients, without obvious adverse reaction.
【CateGory Index】： R743.33